Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Scott Biller sold 2,146 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $60.79, for a total transaction of $130,455.34. Following the sale, the insider now directly owns 8,410 shares in the company, valued at approximately $511,243.90. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Scott Biller also recently made the following trade(s):

  • On Wednesday, November 1st, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $62.69, for a total transaction of $134,532.74.
  • On Wednesday, October 4th, Scott Biller sold 10,470 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $70.00, for a total transaction of $732,900.00.
  • On Monday, October 2nd, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $67.23, for a total transaction of $144,275.58.
  • On Monday, September 11th, Scott Biller sold 15,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.00, for a total transaction of $975,000.00.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded down $0.93 during trading on Tuesday, reaching $61.33. 301,294 shares of the company’s stock were exchanged, compared to its average volume of 512,803. Agios Pharmaceuticals, Inc. has a 52 week low of $39.24 and a 52 week high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.19. The company had revenue of $11.35 million for the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company’s revenue was up 26.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.63) EPS. equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.59 earnings per share for the current year.

A number of brokerages have commented on AGIO. SunTrust Banks reissued a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. J P Morgan Chase & Co restated a “buy” rating and set a $76.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Royal Bank Of Canada started coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $78.00 target price on the stock. Credit Suisse Group upped their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Finally, Cann restated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Agios Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $75.70.

Large investors have recently made changes to their positions in the stock. QS Investors LLC acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at approximately $144,000. Teacher Retirement System of Texas acquired a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at approximately $225,000. S&CO Inc. acquired a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at approximately $227,000. Cubist Systematic Strategies LLC raised its position in shares of Agios Pharmaceuticals by 1,041.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after acquiring an additional 3,123 shares during the period. Finally, Macquarie Group Ltd. acquired a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at approximately $245,000. Institutional investors and hedge funds own 94.38% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/05/agios-pharmaceuticals-inc-agio-insider-sells-130455-34-in-stock.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.